William Blair Investment Management LLC increased its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 89.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,709,212 shares of the biotechnology company’s stock after purchasing an additional 1,277,616 shares during the period. William Blair Investment Management LLC owned approximately 3.37% of Veracyte worth $124,732,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Bank of America Corp DE boosted its position in Veracyte by 14.7% during the 1st quarter. Bank of America Corp DE now owns 1,448,897 shares of the biotechnology company’s stock worth $46,669,000 after acquiring an additional 185,929 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Veracyte in the second quarter valued at approximately $1,583,000. Congress Asset Management Co. bought a new position in Veracyte during the third quarter worth $89,971,000. Royal Bank of Canada grew its stake in Veracyte by 66.4% in the 1st quarter. Royal Bank of Canada now owns 573,096 shares of the biotechnology company’s stock valued at $18,459,000 after buying an additional 228,720 shares during the last quarter. Finally, Summit Creek Advisors LLC bought a new position in shares of Veracyte during the second quarter worth approximately $6,986,000.
Veracyte Stock Performance
NASDAQ:VCYT opened at $24.33 on Monday. Veracyte, Inc. has a 52-week low of $21.91 and a 52-week high of $60.91. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 15.70 and a beta of 1.98. The business’s fifty day moving average is $42.16 and its 200 day moving average is $42.44.
Veracyte (NASDAQ:VCYT – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.10. The company had revenue of $151.75 million during the quarter, compared to analyst estimates of $147.13 million. Veracyte had a net margin of 21.80% and a return on equity of 8.99%. Veracyte’s revenue was up 15.1% compared to the same quarter last year. During the same period last year, the business earned $0.51 earnings per share. Equities analysts predict that Veracyte, Inc. will post 1.34 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, insider Phillip Febbo sold 13,110 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $43.05, for a total value of $564,385.50. Following the transaction, the insider owned 133,048 shares of the company’s stock, valued at $5,727,716.40. This represents a 8.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Karin Eastham sold 14,850 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $50.00, for a total value of $742,500.00. Following the completion of the transaction, the director directly owned 10,247 shares in the company, valued at approximately $512,350. This represents a 59.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 62,609 shares of company stock worth $2,858,904. 1.60% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Several research analysts have recently commented on the stock. Morgan Stanley lowered their target price on shares of Veracyte from $47.00 to $44.00 and set an “underweight” rating on the stock in a report on Tuesday, August 4th. Piper Sandler reduced their price target on Veracyte from $54.00 to $30.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 10th. Zacks Research lowered shares of Veracyte from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Wolfe Research lowered shares of Veracyte from a “strong-buy” rating to a “hold” rating in a report on Friday, November 6th. Finally, Wall Street Zen downgraded shares of Veracyte from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $44.50.
Read Our Latest Research Report on VCYT
Veracyte Company Profile
Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.
See Also
- Five stocks we like better than Veracyte
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
